Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes cyp3a-reduction: a new strategy for cyp3a-mediated drug hepatotoxicity.
Hepatic CYP450s play an important role in drug-induced hepatotoxicity. They are altered not only in liver diseases but in many non-liver diseases, such as extra-hepatic tumours. Consequently, CYP450-mediated abnormal drug exposure increases the incidence and extent of hepatotoxicity. However, people often underestimate this risk because the mechanisms underlying hepatic CYP450s reduction in extra-hepatic tumours remain unclear. To avoid additional influences of chemical carcinogenesis inducers used in spontaneous tumour mouse models on hepatic CYP450s, we chose mice with subcutaneously transplanted tumours to model extra-hepatic tumours. CYP3A reduction was evaluated by qPCR, western blotting and metabolic activity. LC-Q/TOF-MS and GC-MS were used in combination for analysing liver metabolomics. The contribution of pentose phosphate pathway (PPP) to CYP3A reduction was investigated by chemical interfering and silencing of glucose-6-phosphate dehydrogenase. CYP3A was already inhibited at the early stage of tumour growth when no significant inflammatory response was observed yet. The PPP was predominately disrupted at this non-inflammatory stage. On one hand, the disrupted PPP directly inhibited CYP3A through chk2/p53/p65 pathway at the non-inflammatory stage; on the other hand, it indirectly strengthened the subsequent IL-6-mediated CYP3A reduction at the inflammatory stage. Through PPP recovery with menadione in the non-inflammatory stage, CYP3A reduction could be reversed, which was comparable to that of IL-6 inhibitor tocilizumab. This PPP modulation strategy to alleviate CYP3A-mediated drug hepatotoxicity was validated with dasatinib in vivo. PPP modulation at the non-inflammatory stage might provide a novel and distinctive approach to manage CYP3A-mediated drug hepatotoxicity.